Gastroesophageal Reflux Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major gastroesophageal reflux disease markets are expected to exhibit a CAGR of 1.21% during 2024-2034.
The gastroesophageal reflux disease market has been comprehensively analyzed in IMARC's new report titled "Gastroesophageal Reflux Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gastroesophageal reflux disease refers to a common, chronic condition characterized by frequent episodes of stomach acid refluxing or backing up into the esophagus, which is the connecting tube between the throat and abdomen. The most prevalent symptom of this ailment is heartburn, marked by a burning sensation or discomfort in the chest. Several other indications associated with the illness may include regurgitation (a sour or bitter taste in the mouth), difficulty swallowing, persistent cough, hoarseness, feeling of a lump in the throat, etc. These symptoms typically worsen after eating, lying down, or bending over. The diagnosis of gastroesophageal reflux disease is based on a combination of medical history, clinical features, and a physical examination. A healthcare provider may also perform upper endoscopy procedures, which involve the insertion of a flexible tube with a camera into the esophagus to visually inspect the abdominal lining for any abnormalities or signs of inflammation caused by acid reflux. Several other diagnostic studies, such as the barium swallow test, ambulatory pH testing, esophageal manometry, etc., are further utilized to confirm a diagnosis among patients.
The increasing cases of hiatal hernia which can disrupt the normal functioning of the lower esophageal sphincter leading to acid backflow, are primarily driving the gastroesophageal reflux disease market. Additionally, the rising prevalence of various associated risk factors, such as stress, pregnancy, obesity, asthma, smoking, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, including proton pump inhibitors, antacids, H2 blockers, etc., to block the formation of acid in the stomach and provide longer-lasting relief is further bolstering the market growth. Apart from this, the inflating application of esophageal sphincter augmentation devices owing to their numerous benefits, like preserved anatomy of the abdomen, reduced medication dependency, and improved quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of laparoscopic anti-reflux surgery, which is performed through small incisions using specialized medical instruments to wrap the upper part of the stomach, thereby resulting in minimum scars and faster recovery, is expected to drive the gastroesophageal reflux disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the gastroesophageal reflux disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gastroesophageal reflux disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gastroesophageal reflux disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the gastroesophageal reflux disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the gastroesophageal reflux disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current gastroesophageal reflux disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the gastroesophageal reflux disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the gastroesophageal reflux disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the gastroesophageal reflux disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of gastroesophageal reflux disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of gastroesophageal reflux disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of gastroesophageal reflux disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with gastroesophageal reflux disease across the seven major markets?
What is the size of the gastroesophageal reflux disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of gastroesophageal reflux disease?
What will be the growth rate of patients across the seven major markets?
Gastroesophageal Reflux Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for gastroesophageal reflux disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gastroesophageal reflux disease market?
What are the key regulatory events related to the gastroesophageal reflux disease market?
What is the structure of clinical trial landscape by status related to the gastroesophageal reflux disease market?
What is the structure of clinical trial landscape by phase related to the gastroesophageal reflux disease market?
What is the structure of clinical trial landscape by route of administration related to the gastroesophageal reflux disease market?
The gastroesophageal reflux disease market has been comprehensively analyzed in IMARC's new report titled "Gastroesophageal Reflux Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gastroesophageal reflux disease refers to a common, chronic condition characterized by frequent episodes of stomach acid refluxing or backing up into the esophagus, which is the connecting tube between the throat and abdomen. The most prevalent symptom of this ailment is heartburn, marked by a burning sensation or discomfort in the chest. Several other indications associated with the illness may include regurgitation (a sour or bitter taste in the mouth), difficulty swallowing, persistent cough, hoarseness, feeling of a lump in the throat, etc. These symptoms typically worsen after eating, lying down, or bending over. The diagnosis of gastroesophageal reflux disease is based on a combination of medical history, clinical features, and a physical examination. A healthcare provider may also perform upper endoscopy procedures, which involve the insertion of a flexible tube with a camera into the esophagus to visually inspect the abdominal lining for any abnormalities or signs of inflammation caused by acid reflux. Several other diagnostic studies, such as the barium swallow test, ambulatory pH testing, esophageal manometry, etc., are further utilized to confirm a diagnosis among patients.
The increasing cases of hiatal hernia which can disrupt the normal functioning of the lower esophageal sphincter leading to acid backflow, are primarily driving the gastroesophageal reflux disease market. Additionally, the rising prevalence of various associated risk factors, such as stress, pregnancy, obesity, asthma, smoking, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, including proton pump inhibitors, antacids, H2 blockers, etc., to block the formation of acid in the stomach and provide longer-lasting relief is further bolstering the market growth. Apart from this, the inflating application of esophageal sphincter augmentation devices owing to their numerous benefits, like preserved anatomy of the abdomen, reduced medication dependency, and improved quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of laparoscopic anti-reflux surgery, which is performed through small incisions using specialized medical instruments to wrap the upper part of the stomach, thereby resulting in minimum scars and faster recovery, is expected to drive the gastroesophageal reflux disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the gastroesophageal reflux disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gastroesophageal reflux disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gastroesophageal reflux disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the gastroesophageal reflux disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the gastroesophageal reflux disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current gastroesophageal reflux disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the gastroesophageal reflux disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the gastroesophageal reflux disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the gastroesophageal reflux disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of gastroesophageal reflux disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of gastroesophageal reflux disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of gastroesophageal reflux disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with gastroesophageal reflux disease across the seven major markets?
What is the size of the gastroesophageal reflux disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of gastroesophageal reflux disease?
What will be the growth rate of patients across the seven major markets?
Gastroesophageal Reflux Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for gastroesophageal reflux disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gastroesophageal reflux disease market?
What are the key regulatory events related to the gastroesophageal reflux disease market?
What is the structure of clinical trial landscape by status related to the gastroesophageal reflux disease market?
What is the structure of clinical trial landscape by phase related to the gastroesophageal reflux disease market?
What is the structure of clinical trial landscape by route of administration related to the gastroesophageal reflux disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GASTROESOPHAGEAL REFLUX DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GASTROESOPHAGEAL REFLUX DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GASTROESOPHAGEAL REFLUX DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 GASTROESOPHAGEAL REFLUX DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GASTROESOPHAGEAL REFLUX DISEASE - UNMET NEEDS
10 GASTROESOPHAGEAL REFLUX DISEASE - KEY ENDPOINTS OF TREATMENT
11 GASTROESOPHAGEAL REFLUX DISEASE - MARKETED PRODUCTS
11.1 List of Gastroesophageal Reflux Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Prilosec (Omeprazole) - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Protonix (Pantoprazole) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Prevacid (Lansoprazole) - Takeda
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Nexium (Esomeprazole) - AstraZeneca
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 GASTROESOPHAGEAL REFLUX DISEASE - PIPELINE DRUGS
12.1 List of Gastroesophageal Reflux Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. GASTROESOPHAGEAL REFLUX DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GASTROESOPHAGEAL REFLUX DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GASTROESOPHAGEAL REFLUX DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Gastroesophageal Reflux Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Gastroesophageal Reflux Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Gastroesophageal Reflux Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Gastroesophageal Reflux Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Gastroesophageal Reflux Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Gastroesophageal Reflux Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Gastroesophageal Reflux Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Gastroesophageal Reflux Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
16 GASTROESOPHAGEAL REFLUX DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GASTROESOPHAGEAL REFLUX DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GASTROESOPHAGEAL REFLUX DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GASTROESOPHAGEAL REFLUX DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GASTROESOPHAGEAL REFLUX DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GASTROESOPHAGEAL REFLUX DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 GASTROESOPHAGEAL REFLUX DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GASTROESOPHAGEAL REFLUX DISEASE - UNMET NEEDS
10 GASTROESOPHAGEAL REFLUX DISEASE - KEY ENDPOINTS OF TREATMENT
11 GASTROESOPHAGEAL REFLUX DISEASE - MARKETED PRODUCTS
11.1 List of Gastroesophageal Reflux Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Prilosec (Omeprazole) - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Protonix (Pantoprazole) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Prevacid (Lansoprazole) - Takeda
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Nexium (Esomeprazole) - AstraZeneca
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 GASTROESOPHAGEAL REFLUX DISEASE - PIPELINE DRUGS
12.1 List of Gastroesophageal Reflux Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. GASTROESOPHAGEAL REFLUX DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GASTROESOPHAGEAL REFLUX DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GASTROESOPHAGEAL REFLUX DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Gastroesophageal Reflux Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Gastroesophageal Reflux Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Gastroesophageal Reflux Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Gastroesophageal Reflux Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Gastroesophageal Reflux Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Gastroesophageal Reflux Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Gastroesophageal Reflux Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Gastroesophageal Reflux Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Gastroesophageal Reflux Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Gastroesophageal Reflux Disease - Access and Reimbursement Overview
16 GASTROESOPHAGEAL REFLUX DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GASTROESOPHAGEAL REFLUX DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GASTROESOPHAGEAL REFLUX DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
